Skip to content

Study · Not a test of the peptide alone · 2018

6 results

Anserine/Carnosine Supplementation Preserves Blood Flow in the Prefrontal Brain of Elderly People Carrying APOE e4.

Ding Q, Tanigawa K, Kaneko J, Totsuka M, Katakura Y, Imabayashi E, Matsuda H, Hisatsune T

Aging and disease1 Jun 2018Cited by 33 (Europe PMC)

PMID29896423 (opens in a new tab)PMCIDPMC5988590 (opens in a new tab)DOI10.14336/ad.2017.0809 (opens in a new tab)PepBankPUB-29896423
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

In a previously reported double-blind, randomized controlled trial (RCT), we demonstrated that daily supplementation with anserine (750 mg) and carnosine (250 mg) improves brain blood flow and memory function in elderly people. Here, we conducted a sub-analysis of MRI data and test scores from the same RCT to determine whether anserine/carnosine supplementation specifically benefits elderly people carrying the APOE e4 allele, which is a risk gene for accelerated brain aging and for the onset of Alzheimer's Disease. We collected data from 68 participants aged 65 years or older who received anserine/carnosine supplementation (ACS) or placebo for 12 months. Subjects were assessed at the start and end of the trial using several neuropsychological tests, including the Wechsler Memory Scale-Logical Memory (WMS-LM). We also collected two types of MRI data, arterial spin labeling (ASL) and diffusion tensor imaging (DTI) at the start and end of the trial. We found that ACS significantly preserved verbal memory (WMS-LM, F[1,65] = 4.2003, p = 0.0445) and blood flow at frontal areas of the brain (FWEcluster level, p < 0.001). Sub-analysis based on the APOE4 genotype showed a significant preservation of blood flow (p = 0.002, by ASL analysis) and white-matter microstructure (p = 0.003, by DTI analysis) at prefrontal areas in APOE4+ subjects in the active group, while there was no significant difference between APOE4- subjects in the active and placebo groups. The effect of ACS in preserving brain structure and function in elderly people carrying APOE4 should be verified by further studies.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking L-carnosine.

  1. 01HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome

    In older adults, anserine/carnosine supplementation significantly preserved verbal memory versus placebo.

    In plain wordsIn older adults, the anserine/carnosine combination significantly preserved verbal memory versus placebo.

    Peptide
    L-carnosine
    Outcome
    IncreaseVerbal memory preservation
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    We found that ACS significantly preserved verbal memory (WMS-LM, F[1,65] = 4.2003, p = 0.0445) and blood flow at frontal areas of the brain (FWEcluster level, p < 0.001).
    2 context sentences
    Summary · context
    Here, we conducted a sub-analysis of MRI data and test scores from the same RCT to determine whether anserine/carnosine supplementation specifically benefits elderly people carrying the APOE e4 allele, which is a risk gene for accelerated brain aging and for the onset of Alzheimer's Disease.
    Summary · context
    We collected data from 68 participants aged 65 years or older who received anserine/carnosine supplementation (ACS) or placebo for 12 months.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  2. 02HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome

    In older adults, anserine/carnosine supplementation significantly preserved frontal brain blood flow versus placebo.

    In plain wordsIn older adults, the anserine/carnosine combination significantly preserved frontal brain blood flow versus placebo.

    Peptide
    L-carnosine
    Outcome
    IncreaseFrontal brain blood flow preservation
    Study

    n = 68

    Comparator
    Placebo
    Outcome group
    Cerebral blood flow · Nervous system and cognition

    Source sentences

    Summary
    We found that ACS significantly preserved verbal memory (WMS-LM, F[1,65] = 4.2003, p = 0.0445) and blood flow at frontal areas of the brain (FWEcluster level, p < 0.001).
    2 context sentences
    Summary · context
    Here, we conducted a sub-analysis of MRI data and test scores from the same RCT to determine whether anserine/carnosine supplementation specifically benefits elderly people carrying the APOE e4 allele, which is a risk gene for accelerated brain aging and for the onset of Alzheimer's Disease.
    Summary · context
    We collected data from 68 participants aged 65 years or older who received anserine/carnosine supplementation (ACS) or placebo for 12 months.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  3. 03HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome

    In APOE4-positive older adults, anserine/carnosine supplementation significantly preserved prefrontal blood flow versus placebo.

    In plain wordsIn APOE4-positive older adults, the anserine/carnosine combination significantly preserved prefrontal blood flow versus placebo.

    Peptide
    L-carnosine
    Outcome
    IncreaseAPOE4-positive prefrontal blood flow
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cerebral blood flow · Nervous system and cognition

    Source sentences

    Summary
    Sub-analysis based on the APOE4 genotype showed a significant preservation of blood flow (p = 0.002, by ASL analysis) and white-matter microstructure (p = 0.003, by DTI analysis) at prefrontal areas in APOE4+ subjects in the active group,
    2 context sentences
    Summary · context
    Here, we conducted a sub-analysis of MRI data and test scores from the same RCT to determine whether anserine/carnosine supplementation specifically benefits elderly people carrying the APOE e4 allele, which is a risk gene for accelerated brain aging and for the onset of Alzheimer's Disease.
    Summary · context
    We collected data from 68 participants aged 65 years or older who received anserine/carnosine supplementation (ACS) or placebo for 12 months.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  4. 04HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome

    In APOE4-positive older adults, anserine/carnosine supplementation significantly preserved prefrontal white-matter microstructure versus placebo.

    In plain wordsIn APOE4-positive older adults, the anserine/carnosine combination significantly preserved prefrontal white-matter structure versus placebo.

    Peptide
    L-carnosine
    Outcome
    IncreaseAPOE4-positive white-matter microstructure
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Sub-analysis based on the APOE4 genotype showed a significant preservation of blood flow (p = 0.002, by ASL analysis) and white-matter microstructure (p = 0.003, by DTI analysis) at prefrontal areas in APOE4+ subjects in the active group,
    2 context sentences
    Summary · context
    Here, we conducted a sub-analysis of MRI data and test scores from the same RCT to determine whether anserine/carnosine supplementation specifically benefits elderly people carrying the APOE e4 allele, which is a risk gene for accelerated brain aging and for the onset of Alzheimer's Disease.
    Summary · context
    We collected data from 68 participants aged 65 years or older who received anserine/carnosine supplementation (ACS) or placebo for 12 months.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  5. 05HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome

    In APOE4-negative older adults, prefrontal blood flow did not differ significantly between anserine/carnosine and placebo groups.

    In plain wordsIn APOE4-negative older adults, prefrontal blood flow did not differ significantly between the combination and placebo groups.

    Peptide
    L-carnosine
    Outcome
    No significant changeAPOE4-negative blood flow
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cerebral blood flow · Nervous system and cognition

    Source sentences

    Summary
    Sub-analysis based on the APOE4 genotype showed a significant preservation of blood flow (p = 0.002, by ASL analysis) and white-matter microstructure (p = 0.003, by DTI analysis) at prefrontal areas in APOE4+ subjects in the active group, while there was no significant difference between APOE4- subjects in the active and placebo groups.
    2 context sentences
    Summary · context
    Here, we conducted a sub-analysis of MRI data and test scores from the same RCT to determine whether anserine/carnosine supplementation specifically benefits elderly people carrying the APOE e4 allele, which is a risk gene for accelerated brain aging and for the onset of Alzheimer's Disease.
    Summary · context
    We collected data from 68 participants aged 65 years or older who received anserine/carnosine supplementation (ACS) or placebo for 12 months.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  6. 06HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome

    In APOE4-negative older adults, white-matter microstructure did not differ significantly between anserine/carnosine and placebo groups.

    In plain wordsIn APOE4-negative older adults, white-matter structure did not differ significantly between the combination and placebo groups.

    Peptide
    L-carnosine
    Outcome
    No significant changeAPOE4-negative white-matter microstructure
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Sub-analysis based on the APOE4 genotype showed a significant preservation of blood flow (p = 0.002, by ASL analysis) and white-matter microstructure (p = 0.003, by DTI analysis) at prefrontal areas in APOE4+ subjects in the active group, while there was no significant difference between APOE4- subjects in the active and placebo groups.
    2 context sentences
    Summary · context
    Here, we conducted a sub-analysis of MRI data and test scores from the same RCT to determine whether anserine/carnosine supplementation specifically benefits elderly people carrying the APOE e4 allele, which is a risk gene for accelerated brain aging and for the onset of Alzheimer's Disease.
    Summary · context
    We collected data from 68 participants aged 65 years or older who received anserine/carnosine supplementation (ACS) or placebo for 12 months.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.